Merck Buys Cough Drug Developer for $1.25B
The acquisition of Afferent Pharmaceuticals gives Merck access to a drug candidate for treating neurogenic conditions including chronic cough.
Biotech Investor Accused of Stealing $18M
A controller and chief legal officer also played 'integral roles' in the scheme, says the SEC.
Biotech CFO Accused of Misleading Investors
The ex-CFO of Aveo Pharmaceuticals and other top executives allegedly failed to disclose FDA concerns about an experimental cancer drug.
IPO Drought Ends With Two Biotech Deals
In the first U.S. offerings since December, U.S. and Chinese biotech firms raised about $252 million.